Sumitomo Pharma Oncology
A U.S.-based biopharmaceutical company focused on discovery, development, and commercialization of therapies across oncology, women’s health, urology, rare disease, CNS, and cell & gene / regenerative medicine. The organization maintains in-house technology platforms and data analytics to support research and de-risk development programs, operates a clinical pipeline spanning preclinical to late-stage studies, and maintains compliance, information security, and distribution programs to support commercialization and patient access.
Industries
Nr. of Employees
medium (51-250)
Sumitomo Pharma Oncology
Cambridge, Massachusetts, United States, North America
Patents
CDK9 inhibitors and polymorphs thereof for use as agents for treatment of cancer
US-12077554-B2
View DetailsCompositions comprising PKM2 modulators and methods of treatment using the same
US-11712433-B2
View Details
CDK9 inhibitors and polymorphs thereof for use as agents for treatment of cancer
US-12077554-B2
View DetailsCompositions comprising PKM2 modulators and methods of treatment using the same
US-11712433-B2
View DetailsProducts
Commercial therapeutics across multiple therapeutic areas
Marketed prescription therapies serving oncology, urology, women’s health, CNS, and rare disease indications.
Regenerative medicine / processed tissue therapy
Development and commercialization of regenerative medicine products, including processed tissue therapies intended for rare pediatric immune disorders.
Commercial therapeutics across multiple therapeutic areas
Marketed prescription therapies serving oncology, urology, women’s health, CNS, and rare disease indications.
Regenerative medicine / processed tissue therapy
Development and commercialization of regenerative medicine products, including processed tissue therapies intended for rare pediatric immune disorders.
Services
Design and execution support for preclinical and clinical programs across multiple therapeutic areas.
Process for physicians to request access to investigational products outside of clinical trials, including documentation review and safety evaluation.
Provision of medical information and adverse event reporting channels for clinicians and patients, with processes to forward safety information to regulators.
In-house analytics capabilities to accelerate insights in discovery and de-risk development and commercialization programs.
Design and execution support for preclinical and clinical programs across multiple therapeutic areas.
Process for physicians to request access to investigational products outside of clinical trials, including documentation review and safety evaluation.
Provision of medical information and adverse event reporting channels for clinicians and patients, with processes to forward safety information to regulators.
In-house analytics capabilities to accelerate insights in discovery and de-risk development and commercialization programs.
Expertise Areas
- Clinical trial management
- Regulatory compliance and corporate compliance programs
- Pharmacovigilance and medical information
- Oncology drug development
Key Technologies
- Cell and gene therapy
- Induced pluripotent stem (iPS) cell research
- Regenerative medicine
- Data analytics platforms for research
News & Updates
Announcement that an investigational oncology asset received orphan drug designation from the U.S. FDA for acute lymphoblastic leukemia.
Certification as a Great Place to Work for the period July 2026–July 2027.
Announcement that the first patient received treatment in a Phase 1/2a clinical study for an investigational regenerative medicine therapy for retinitis pigmentosa.
Certified as a Great Place to Work for July 2026–July 2027 (U.S.).
Announcement that an investigational oncology asset received orphan drug designation from the U.S. FDA for acute lymphoblastic leukemia.
Certification as a Great Place to Work for the period July 2026–July 2027.
Announcement that the first patient received treatment in a Phase 1/2a clinical study for an investigational regenerative medicine therapy for retinitis pigmentosa.
Certified as a Great Place to Work for July 2026–July 2027 (U.S.).